C&G Editor in Chief, Erin Harris

  1. Disciplined CGT Will Win On 2026 Regulatory Flexibility 1/29/2026

    Wilson Bryan, M.D., and Daniela Drago, Ph.D., RAC, joined our our first Cell & Gene Live of 2026 to unpack what a more mature era of regulatory oversight means for sponsors.

  2. ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026 1/12/2026

    ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.

  3. Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/7/2026

    Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.

  4. Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost 12/18/2025

    Our recent Cell & Gene Live, Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing, explored how developers and CDMOs are navigating multi-modal manufacturing decisions, balancing cost, capacity, risk, and long-term commercial viability.

  5. CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B 12/12/2025

    CSL's Dr. Deborah Long and Diego Sacristan highlight HEMGENIX's five-year Phase 3 data as a watershed for hemophilia B gene therapy.

  6. Cell 2025, Advanced Therapies USA Taught Me Why Platformization Is No Longer Optional 12/10/2025

    True scalability and global-ready CGT manufacturing depends on platformization that tightly integrates MES, ERP, LIMS, and related systems into a harmonized, leadership-driven digital backbone that treats data as a strategic asset.

  7. Why Early Manufacturing Decisions in Cell & Gene Therapy Matter 11/20/2025

    Our Cell & Gene Live covered why early manufacturing decisions in cell and gene therapy are crucial, as they set the stage for future scalability, quality, and commercial success.

  8. How Early Manufacturing Decisions Shape Long-Term Success 10/27/2025

    Early manufacturing choices in cell and gene therapy shape long-term clinical and commercial success, so leaders from Allogene and Verismo emphasized that both autologous and allogeneic developers should prioritize process simplicity, risk-based decision-making, and adaptable manufacturing as therapies move from concept to clinic.

  9. Understanding CLL And SLL Treatment Evolution 10/10/2025

    Tevogen Bio's Dr. Neal Flomenberg and Dr. Dolores Grosso discuss the shift from chemotherapy to targeted therapies such as Jaypirca and highlight Tevogen’s antigen-specific T cell platform as a new frontier in cancer and infectious disease treatment.

  10. Advancing Telomere Targeting Therapy For Non-Small Cell Lung Cancer 10/3/2025

    MAIA Biotechnology's Dr. Vlad Vitoc shares insights into how the company is advancing a novel therapeutic strategy that could redefine the treatment landscape for hard-to-treat cancers.